Key pipeline developments
- Successful Phase II results of studies in the US and Philippines of our rabies antibody combination, showing safety and tolerability. Third Phase II study in India in progress.
- Encouraging results from the Phase I Ad35 tuberculosis vaccine study, showing that CD8 immune responses are considerably higher than ever seen in a tuberculosis vaccine study. Program entered Phase II clinical testing.
- Alternative adenovirus serotypes like Ad26 and Ad35 using Crucell’s AdVac®/PER.C6® technologies were used to express protein of SIV (HIV-like virus). Study showed strong T-cell immune response and provides protection against SIV. Malaria and TB vaccines in development using Ad26 and Ad35.
- Crucell’s monoclonal antibodies (mAb) against influenza strongly outperforms the anti-influenza drug oseltamivir in pre-clinical tests.
